Darlena Banas
Family · South Miami, FLNPI 1831442607
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (51.0%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Fresenius USA Marketing, Inc. accounts for 69.5% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2023 at $32,726 and has fallen 88.5% since, to $3,768 in 2025. Among family clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 256 payments — averaging $248.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Fresenius USA Marketing, Inc.$44K
- GSK$13K
- Vifor Pharma, Inc.$2K
- Amgen$1K
- AstraZeneca$1K
- Ardelyx, Inc.$448
- plus $2K from 14 others
What the payments were for
- Consulting fees$14,75023%
- Speaking & faculty fees$32,50051%
- Travel & lodging$7,52512%
- Food & beverage$8,92714%
- Education$60%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Fresenius USA Marketing, Inc. | 103 | $44,278 |
| GSK | 15 | $13,361 |
| Vifor Pharma, Inc. | 30 | $1,634 |
| Amgen(2 entities) | 19 | $1,097 |
| AstraZeneca | 26 | $1,040 |
| Ardelyx, Inc. | 13 | $448 |
| Calliditas Therapeutics US Inc. | 2 | $251 |
| Bayer | 12 | $240 |
| Mallinckrodt Hospital Products Inc. | 6 | $235 |
| Akebia Therapeutics Inc | 5 | $206 |
| Otsuka America Pharmaceutical, Inc. | 4 | $189 |
| Novartis | 9 | $185 |
| Cormedix Inc. | 2 | $124 |
| Apellis Pharmaceuticals, Inc. | 1 | $104 |
| Sanofi | 1 | $95 |
| Aurinia Pharma U.S., Inc. | 3 | $80 |
| Travere Therapeutics, Inc. | 1 | $55 |
| Pfizer | 2 | $43 |
| Boston Scientific | 1 | $26 |
| Novo Nordisk | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$63,708 in reported general payments places this provider in the 95th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 225 | $593,175 |
| VeltassaPatiromer Calcium Sorbitex | 128 | $129,060 |
| LokelmaSodium Zirconium Cyclosilicate | 86 | $70,700 |
| AuryxiaFerric Citrate | 44 | $63,620 |
| Sevelamer Carbonate | 387 | $58,620 |
| XphozahTenapanor Hcl | 13 | $47,851 |
| FarxigaDapagliflozin Propanediol | 31 | $33,673 |
| Lanthanum Carbonate | 27 | $21,589 |
| Midodrine Hcl | 75 | $8,565 |
| Calcium Acetate | 59 | $6,780 |
| Nifedipine ErNifedipine | 162 | $4,982 |
| Bumetanide | 77 | $3,665 |
| Doxazosin Mesylate | 73 | $1,099 |
| Potassium Chloride | 45 | $1,078 |
| Losartan Potassium | 99 | $1,019 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $44,278 | $593,175225 claims |
| AstraZenecaLokelma, Farxiga | $1,040 | $104,373117 claims |
| Akebia Therapeutics IncAuryxia | $206 | $63,62044 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 14,618 family providers in Florida.
Other family in South Miami
- Naime Reyno RamosSouth Miami$44K
- Lewis HarringtonTampa$954K
- Danielle PharesFt Lauderdale$713K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
- Deena RodneyMaitland$323K
- Yamila MelendezMiami$212K
- Holly BoydLand O Lakes$200K
- Rachael BuschLoxahatchee$189K
- Victor Tatis de la NuezMiramar$161K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.